Malaria is one of the greatest causes of mortality worldwide. Use of the most effective treatments for malaria remains inadequate for those in need, and there is concern over the emergence of resistance to these treatments. In 2010, the Global Fund launched the Affordable Medicines Facility-malaria (AMFm), a series of national-scale pilot programmes designed to increase the access and use of quality-assured artemisinin based combination therapies (QAACTs) and reduce that of artemisinin monotherapies for treatment of malaria. AMFm involves manufacturer price negotiations, subsidies on the manufacturer price of each treatment purchased, and supporting interventions such as communications campaigns.
|
|
|
Significant progress has been made in recent years in the fight against malaria. Since 2000, mortality from malaria has decreased by over 25 percent globally. Scale-up of effective malaria interventions, including the use of artemisinin-based combination therapies - the most effective drug for treating the disease - have been instrumental to this success. However, growing resistance to artemisinins by the malaria parasite has been emerging in Southeast Asia and is threatening to reverse the gains that have been made to date. In this interview, Senior Technical Officer at Malaria Consortium, Dr Prudence Hamade, explains how dangerous a spread the spread of parasite resistance to anti-malarial drugs could be in Asia and beyond.
|
A new diagnostic test could revolutionize the treatment of malaria, one of the world's most persistent and deadly diseases, making it possible to diagnose the illness from a single drop of blood or saliva. The test, developed by researchers at Aarhus University in Denmark, detects very low levels of an enzyme produced by the Plasmodium parasite, the organism that causes malaria. This could allow intervention before an outbreak develops, researchers say. Read More
|
Also on FightingMalaria.org
|
|
|
|
No comments:
Post a Comment